NEW YORK (TheStreet) -- RATINGS CHANGES

AmerisourceBergen (ABC) was upgraded to buy by TheStreet Ratings. You can view the full analysis from the report here: ABC Ratings Report.

Cigna (CI) was upgraded to buy from neutral by Sterne Agee, which set a $190 price target, saying Cigna's risk-reward profile exceptionally compelling given the announced merger with Anthem (ANTM).

CNX Coal Resources (CNXC) was started at outperform by Credit Suisse, which set a $22 price target, citing good assets and a challenging industry.

DealerTrack Techonlogies (TRAK) was downgraded to market perform from outperform by Wells Fargo said, which gave a valuation range $63 to $64. The downgrade reflects the pending acquisition by Cox Automotive, a provider of digital marketing, wholesale and ecommerce solutions for the automotive industry, Wells Fargo said.

Flotek Industries (FTK) was upgraded to perform from underperform by Oppenheimer, which set a $17 price target, saying that second-quarter results were exceptionally strong and the company appears to have reached a "tipping point" where Flotek believes it has convinced operators of the efficacy and value of its CnF.

Lear Corp. (LEA) was upgraded to buy from hold by Deutsche Bank, which set a $122 price target, saying that risks are positively skewed for the intermediate term.

Monster Beverage (MNST) was upgraded to buy by TheStreet Ratings. You can view the full analysis from the report here: MNST Ratings Report.

Qualcomm (QCOM) was upgraded to overweight from equal weight by Morgan Stanley, which set a $75 price target. The upgrade comes as a result of continued market leadership, more positive chip industry structure and conditions, multiple upside drivers to estimates and an attractive valuation, Morgan Stanley said.

Quality Systems (QSII) was upgraded to sector perform from underperform by RBC Capital Markets, which set a $14 price target. The price target has been achieved and significant challenges remain, RBC said.

Sunesis Pharmaceuticals (SNSS) was downgraded to hold from buy by Cantor Fitzgerald, which set a $2 price target, citing disappointing FDA guidance that will require new clinical data to be generated before an NDA for QINPREZO can be submitted.

Ultragenyx Pharmaceutial (RARE) was downgraded to equal weight from overweight by Morgan Stanley, which set a $126 price target, saying that valuation is stretched, increasing execution risk on the pipeline.

Ventas (VTR) was upgraded to outperform from market perform by BMO, which set a $74 price target ahead of the spinoff of Care Capital Properties in September, which should be a catalyst for a re-rating.

Weatherford International (WFT) was upgraded to equal weight from underweight by Barclays, which set a $12 price target, saying that downside risk is mitigated.

More from Stocks

Dow Seeks Direction as Bond Yields Inch Closer to 3% Threshold

Dow Seeks Direction as Bond Yields Inch Closer to 3% Threshold

Should You Invest In DowDuPont Now?

Should You Invest In DowDuPont Now?

Newell Settles With Starboard, Adds 3 Directors While Keeping Icahn Happy Too

Newell Settles With Starboard, Adds 3 Directors While Keeping Icahn Happy Too

Should You Fear Earnings From Mega-Cap Tech Names Like Google and Microsoft?

Should You Fear Earnings From Mega-Cap Tech Names Like Google and Microsoft?

Why the Stock Market Won't Crash When 10-Year Yields Smash Through 3%

Why the Stock Market Won't Crash When 10-Year Yields Smash Through 3%